Form 4 for RLMD RELMADA THERAPEUTICS, INC.
Accepted 2025-12-16 00:00:00 ET · period of report 2025-12-12 · accession 0001213900-25-121973 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-16 | 2025-12-15 | RLMD | Shenouda Maged | CFO | P - Purchase | $4.12 | +11.7K | 800.0K | +1% | +$48.1K |
| D | 2025-12-16 | 2025-12-12 | RLMD | Shenouda Maged | CFO | A - Grant | $0.00 | +828.0K | 828.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-15 | P | A | 11,665 | $4.12 | 800,000 | D | — | — | |
| 2 | Derivative | Stock Appreciation Rights | 2025-12-12 | A | A | 828,000 | $0.00 | 828,000 | D | $4.06 · 2026-03-12 to 2035-12-12 | 828,000 Common Stock | (F1) The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026. |